1. Sanz MA, Montesinos P: How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123 (18): 2777-82, 2014.

2. Montesinos P, Bergua JM, Vellenga E, et al.: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113 (4): 775-83, 2009.

3. Coombs CC, DeAngelis LM, Feusner JH, et al.: Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria. Clin Lymphoma Myeloma Leuk 16 (3): 146-51, 2016.

4. de Botton S, Coiteux V, Chevret S, et al.: Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 22 (8): 1404-12, 2004.

5. Unnikrishnan D, Dutcher JP, Varshneya N, et al.: Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97 (5): 1514-6, 2001.

6. Barbey JT: Cardiac toxicity of arsenic trioxide. Blood 98 (5): 1632 - 1634, 2001.

7. Детская гематология Под ред: А.Г. Румянцева, А.А. Масчана, Е.В. Жуковской. 2015. 656 p.

8. Pui C.-H. Childhood leukemias. 2012. 880 p.

9. C. Gurnari, М.T. Voso, K. Girardi, A. Mastronuzzi and L. Strocchio. Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. Int. J. Mol. Sci. 2021, 22, 642.

10. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t (15; 17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Group Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics. Blood, 2000; 96: 1297-308.

11. Melnick, A.; Licht, J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93, 3167 - 3215.

12. Zhao, J.; Liang, J.W.; Xue, H.L.; Shen, S.H.; Chen, J.; Tang, Y.J.; Yu, L.S.; Liang, H.H.; Gu, L.J.; Tang, J.Y.; et al.; et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia 2019, 33, 1387 - 1399.

13. Shallis R.M. et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.//Blood Rev. 2019. Vol. 36. P. 70 - 87.

14. Testi, A.M.; Pession, A.; Diverio, D.; Grimwade, D.; Gibson, B.; de Azevedo, A.C.; Moran, L.; Leverger, G.; Elitzur, S.; Hasle, H.; et al. Risk-adapted treatment of acute promyelocytic leukemia: Results from the International Consortium for Childhood APL. Blood 2018, 132, 405 - 412.

15. Maule, M.; Dama, E.; Mosso, M.L.; Magnani, C.; Pastore, G.; Merletti, F. High incidence of acute promyelocytic leukemia in children in northwest Italy, 1980 - 2003: A report from the Childhood Cancer Registry of Piedmont. Leukemia 2008, 22, 439 - 441.

16. Corea, A.M.; Espinoza, C.P.; Rajnoldi, A.C.; Conter, V.; Lietti, G.; Masera, G.; Sessa, C.; Cavalli, F.; Biondi, A.; Rovelli, A. Childhood acute promyelocytic leukemia in Nicaragua. Ann. Oncol. 1993, 4, 892 - 894.

17. ; Schuttenberg, V.; Armendariz, H.; Alba, L.; Martinez, M.; Fynn, A.; ; , A. Childhood acute leukemia: A single institution experience in La Plata, Argentina. Med. Pediatr. Oncol. 2001, 36, 383 - 385.

18. Creutzig, U.; Zimmermann, M.; Reinhardt, D.; Rasche, M.; von Neuhoff, C.; Alpermann, T.; Dworzak, M.; , K.; Zemanova, Z.; Tchinda, J.; et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer 2016, 122, 3821 - 3830.

19. Testi, A.M.; Coco, F.L.; D'Angi, M.; Locatelli, F.; Pession, A. Acute promyelocytic leukemia (APL): Comparison between children and adults. Mediterr. J. Hematol. Infect. Dis. 2014, 6, e2014032.

20. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms//Blood. 2016.

21. Arber D.A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia//Blood. 2016.

22. Sanz M.A. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.//Blood. 2009. Vol. 113, N 9. P. 1875 - 1891.

23. Савченко В.Г., Паровичникова Е.Н. Острый промиелоцитарный лейкоз. М.: Литерра, 2010. 200 p.

24. Паровичникова Е.Н., Соколов А.Н., Савченко В.Г. Протокол лечения острого промиелоцитарного лейкоза AIDA//Программное лечение заболеваний крови, под ред. Савченко В.Г. 2012. P. 265 - 287.

25. Jae H. Park et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, august 4, 2011, volume 118, number 5, pp. 1248 - 1254.

26. Jill S. Menell et al. Annexin II and Bleeding in Fcute Promyelocytic Leukemia. NEJM, 1999, Vol 340, N 13, pp. 994 - 1004.

27. Tiziano Barbui, Guido Finazzi, Anna Falanga The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia, Blood, Volume 91, Issue 9, 1 May 1998, Pages 3093 - 3102.

28. P Fenaux Management of acute promyelocytic leukemia, Eur J Haematol., 1993 Feb; 50(2): 6.

29. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы//Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А. 2-е изд., перераб. и доп. 2007. P. 409 - 502.

30. Godley L.A. Inherited predisposition to acute myeloid leukemia.//Semin. Hematol. 2014. Vol. 51, N 4. P. 306 - 321.

31. Rubnitz J.E., Gibson B., Smith F.O. Acute Myeloid Leukemia//Hematology/Oncology Clinics of North America. 2010. Vol. 24, N 1. P. 35 - 63.

32. Creutzig U. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel//Blood. American Society of Hematology, 2012. Vol. 120, N 16. P. 3167 - 3205.

33. Miguel A. Sanz et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet Blood(R) 11 APRIL 2019 VOLUME 133, NUMBER 15, pp. 1630 - 1643.

34. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival//Blood. 2009. Vol. 113, N 17. P. 3911 - 3917.

35. Муфтахова Г.М., Аксенова М.Е. Поздние эффекты противоопухолевой терапии со стороны мочеполовой системы (отсроченное влияние противоопухолевой терапии на органы мочеполовой системы)//Российский журнал детской гематологии и онкологии. 2019. Vol. 5, N 4. P. 114 - 119.

36. Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia//HIV-Associated Hematological Malignancies. 2016. P. 133 - 144.

37. Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection.//Hepatology. 2001. Vol. 34, N 4 Pt 1. P. 809 - 816.

38. Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?//Leuk. Res. 1997. Vol. 21, N 8. P. 785 - 788.

39. Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2 - 2020. [Electronic resource].

40. Lam M.T. et al. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study.//Cancer. 1981. Vol. 48, N 10. P. 2168 - 2171.

41. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011)//Haematologica. 2013. Vol. 98, N 12. P. 1836 - 1847.

42. Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia//Haematologica. 2013. Vol. 98, N 12. P. 1826 - 1835.

43. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice.//Intern. Med. J. 2012. Vol. 42, N 3. P. 332 - 338.

44. D hner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel//Blood. 2017. Vol. 129, N 4. P. 424 - 447.

45. Brain B.J. Acute promyelocytic leukemia//Leukemia Diagnosis/ed. Brain B.J. Blackwell Science, 1999. P. 14 - 19.

46. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).//Leukemia. 1995. Vol. 9, N 10. P. 1783 - 1786.

47. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia//Blood. 2009. Vol. 114, N 25. P. 5126 - 5135.

48. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999; 94(1): 12 - 22.

49. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002; 16(10): 1959 - 1973.

50. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12): 1275 - 1291.

51. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009; 27(22): 3650 - 3658.

52. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual diseasedirected therapy in acute myeloid leukemia. Semin Oncol. 2008; 35(4): 388 - 400.

53. Cicconi L, Divona M, Ciardi C, et al. PML-RARa kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016; 30(10): 1987 - 1992.

54. Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology//Mayo Clin. Proc. 2014. Vol. 89, N 9. P. 1287 - 1306.

55. Roberts A.S. et al. Extramedullary haematopoiesis: radiological imaging features//Clinical Radiology. 2016. Vol. 71, N 9. P. 807 - 814.

56. Fritz J. et al. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults.//AJR. Am. J. Roentgenol. 2007. Vol. 189, N 1. P. 209 - 218.

57. Arrigan M. et al. Imaging findings in recurrent extramedullary leukaemias//Cancer Imaging. 2013. Vol. 13, N 1. P. 26 - 35.

58. Almond L.M. et al. Myeloid Sarcoma: Presentation, Diagnosis, and Treatment//Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc., 2017. Vol. 17, N 5. P. 263 - 267.

59. Winestone L.E. et al. Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment//Leuk. Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, N 9. P. 2190 - 2198.

60. O. Abla1, R.C. Ribeiro. How I Treat Children and Adolescents with Acute PromyelocyticLeukaemia. Br J Haematol. 2014 January; 164(1): 24 - 38.

61. Park J.H. et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.//Blood. 2011. Vol. 118, N 5. P. 1248 - 1254.

62. Lehmann S. et al. Continuing high early death rate in acute promyelocytic leukemia: a Population-based report from the Swedish Adult Acute Leukemia Registry.//Leukemia. 2011. Vol. 25, N 7. P. 1128 - 1134.

63. C.Gurnari et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. British Journal of Haematology, 2021, 193, 129 - 132.

64. R.Abrah o, R.C. Ribeiro et al. Early mortality and survival improvements of adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis. Harmatologica, 2022; 107(3), 733 - 736.

65. Mantha S., Tallman M.S., Soff G.A. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?//Curr. Opin. Hematol. 2016. Vol. 23, N 2. P. 121 - 126.

66. Mantha S. et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.//Blood. 2017. Vol. 129, N 13. P. 1763 - 1767.

67. Meijer K. et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa.//Arch. Intern. Med. 2000. Vol. 160, N 14. P. 2216 - 2217.

68. Pemmaraju N. et al. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.//Front. Oncol. 2015. Vol. 5. P. 29.

69. Самочатова Е.В., Масчан А.А., Алейникова О.В., Тарасевич И.С. и др. Опыт лечения промиелоцитарного лейкоза у детей по протоколу с использованием трансретиноевой кислоты: результаты клиник России и Беларуси. Гематология и трансфузиология. 2000; 45, N 1: 6 - 10.

70. Самочатова Е.В., Масчан А.А, Алейникова О.В. с соавт. Долгосрочные результаты комбинированного лечения острого промиелоцитарного лейкоза у детей и подростков с использованием геннонаправленной терапии: Терапевтический архив, 2007, т. N 7, с. 26 - 30.

71. Zhen-Yi Wang and Zhu Chen1 Acute promyelocytic leukemia: from highly fatal to highly curable. BLOOD, 1 MARCH 2008 _ VOLUME 111, NUMBER 5.

72. Li X. et al. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis//Hematology. Taylor and Francis Ltd., 2017. Vol. 22, N 8. P. 450 - 459.

73. Fenaux P. et al. Long-term follow-up confirms the benefit of all-trans retinoic acid inacute promyelocytic leukemia. European APL group.//Leukemia. 2000. Vol. 14, N 8. P. 1371 - 1377.

74. Fenaux P. et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.//Blood. 1999. Vol. 94, N 4. P. 1192 - 1200.

75. Lo-Coco F. et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group//Blood. 2010. Vol. 116, N 17. P. 3171 - 3179.

76. Паровичникова Е.Н., Троицкая В.В., Соколов А.Н., Клясова Г.А., Галстян Г.М., Кузьмина Л.А., Домрачева Е.В., Двирнык В.Н., Савченко В.Г. Лечение взрослых больных острым промиелоцитарным лейкозом по протоколу AIDA.//Терапевтический архив. 2013. Т. 85. N 7. С. 10 - 17.

77. Самочатова Е.В., Байдильдина Д.Д., Масчан М.А., Савва Н.Н., Хлебникова О.П., Шамардина А.В., Марейко Ю.Е., Цаур Г.А., Ригер Т.О., Шнейдер М.М., Румянцева Ю.В., Наседкина Т.В., Савицкая Т.В., Масчан А.А. Эффективность терапии острого промиелоцитарного лейкоза у детей с использованием полностью трансретиноевой кислоты, цитозин-арабинозида и сниженных доз антрациклинов. Онкогематология. 2008; (3): 8 - 17.

78. А.В. Беспалова, Е.В. Самочатова, О.В. Алейникова, Д.Д. Байдильдина, Г.А. Новичкова, М.А. Масчан, Е.В. Сунцова, О.А. Тиганова, А.В. Шамардина, Л.Г. Фечина, О.В. Стренева, Г.П. Павлова, Н.С. Осмульская, Г.М. Сычева, Т.В. Феоктистова, Н.В. Чаплыгина, А.А. Масчан "Результаты лечения острого промиелоцитарного лейкоза у детей и подростков по данным мультицентрового исследования (Беларусь-Россия). Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2005, т. 4, N 1: с. 25 - 31.

79. U. Creutzig et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses Report from the AML-BFM Study Group. British Journal of Haematology, 2010, 149, 399 - 409.

80. Lo-Coco F et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New Engl J Med. (2013) 369: 111 - 21. doi: 10.1056/NEJMoa1300874.

81. Platzbecker U. et al. Improved Outcomes With ATRA and ATO compared with ATRA and Chemo in non-high-risk APL_Final Results of APL0406 trial//J. Clin. Oncol, 2017. Vol. 35, N 6. P. 605 - 612.

82. Shannon E. Conneely and Alexandreta M. Stevens, Advances in Pediatric Acute Promyelocytic Leukemia. Children 2020, 7, 11; doi: 10.3390/children7020011.

83. Huyong Zheng et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. J Clin Oncol, 2021, 39: 3161 - 3170.

84. Alan K Burnett et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16: 1295 - 1305.

85. Matthew A. Kutny et al. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia A Report From the Children's Oncology Group AAML1331 Trial. JAMA Oncol. 2022; 8(1): 79 - 87.

86. Huai-Yu Wang et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood Cancer Journal (2022) 12: 158.

87. Zappasodi P. et al. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement. Annals of Hematology 90, 5 (2010) 595 - 597.

88. Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H, Ohyashiki K. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2009 Sep 3.

89. Knipp S, Gattermann N, Schapira M, K ferstein H, Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res. 2007 Nov; 31(11): 1585-7.

90. Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008 Nov 1; 112(9): 3587-90.

91. Sanz M.A., Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.//Blood. 2014. Vol. 123, N 18. P. 2777 - 2782.

92. Jie-Si Luo et al. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia. Annals of Hematology https://doi.org/10.1007/s00277-023-05270-x.

93. Ashley C. Woods and Kelly J. Norsworthy, Differentiation Syndrome in Acute Leukemia: APL and Beyond. Cancers 2023, 15, 4767.

94. Wang Q. et al. Venetoclax for arsenic-resistant acute promyelocytic leukaemia. Br J Haematol. 2022 Feb 17. pp 1 - 3.

95. Zhang X. et al. Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report. Front. Oncol., 05 July 2021, Volume 11, pp 1 5.

96. Gill H. et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.//Cancer. 2018. Vol. 124, N 11. P. 2316 - 2326.

97. Lengfelder E. et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet//Leukemia. 2015. Vol. 29, N 5. P. 1084 - 1091.

98. Ganzel C. et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2//Bone Marrow Transplant. Nature Publishing Group, 2016. Vol. 51, N 9. P. 1180 - 1183.

99. Ramadan S.M. et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era//Haematologica. 2012. Vol. 97, N 11. P. 1731 - 1735.

100. Furuya A. et al. Central nervous system involvement of acute promyelocytic leukemia, three case reports//Clin. Case Reports. Wiley, 2017. Vol. 5, N 5. P. 645 - 653.

101. Kulkarni U. et al. A phase II study evaluating the role of bortezomib in the Management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Med. 2020 Apr; 9(8): 2603 - 2610.

102. Ganesan S. et al. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016 Nov; 30(11): 2169 - 2178.

103. Детская гематология Под ред: А.Г. Румянцева, А.А. Масчана, Е.В. Жуковской. 2015. с. 374.

104. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. 2009. с. 448.

105. Coiffier B. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review//Journal of Clinical Oncology. 2008. Vol. 26, N 16. P. 2767 - 2778.

106. Cairo M.S. et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus//Br. J. Haematol. 2010. Vol. 149, N 4. P. 578 - 586.

107. Детская онкология. Национальное руководство. Под ред. М.Д. Алиева, В.Г. Полякова, Г.Л. Менткевича, С.А. Маяковой. М.: Издательская группа РОНЦ. Практическая медицина, 2012. с. 684.

108. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011)//Haematologica. 2013. Vol. 98, N 12. P. 1836 - 1847.

109. Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia//Haematologica. 2013. Vol. 98, N 12. P. 1826 - 1835.

110. Korula A. et al. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country//Mycoses. Blackwell Publishing Ltd, 2017. Vol. 60, N 10. P. 686 - 691.

111. Fisher B.T. et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease among Children and Young Adults with Acute Myeloid Leukemia: A Randomized Clinical Trial//JAMA - J. Am. Med. Assoc. American Medical Association, 2019. Vol. 322, N 17. P. 1673 - 1681.

112. Mandhaniya S. et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: A prospective, randomized, clinical study//J. Pediatr. Hematol. Oncol. 2011. Vol. 33, N 8. P. e333-41.

113. Cornely O.A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia//N. Engl. J. Med. Massachussetts Medical Society, 2007. Vol. 356, N 4. P. 348 - 359.

114. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer, 2006; 106(10): 2258 - 2266.

115. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C et al. Aetiology and resistance in bacteriaemias among adult and paediatric haematology and cancer patients. Jornal of infection (2014), 68: 321 - 331.

116. Lyman GH, Rolston KVI. How we treat febrile neutropenia in patients receiving cancer chemotherapy. Journal of oncology practice, 2010; 6(3): 149 - 152.

117. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference of Infections in Luekemia. Нaematologica 2013; 98 (12): 1826 - 1835.

118. De la Court J.R. et al The Dutch working party on antibiotic policy (SWAB) recommendation for the diagnosis and management of febrile neutropenia in patients with cancer.// Infect Dis Ther 2022; 11(6): 2063 - 2098.

119. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol, 2009; 31(9): 623 - 629.

120. Hartman S et al A new Framework to implement model-informed dosing in clinical guidelines: piperacillin and amikacin as proof of concept.//Front Pharmacol 2020; 11: 592204.

121. Miranda M., Nadel S. Pediatric Sepsis: a Summary of Current Definitions and Management Recommendations//Curr Pediatr Rep. Springer Nature, 2023. Vol. 11, N 2. P. 29 - 39.

122. Lehrnbecher et al. Clinical practice guidelines for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol 2020 Sep 20; 38(27): 3205 - 3216.

123. Simon A. et al. Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?//GMS Hyg Infect Control. German Medical Science, 2016. Vol. 11. P. Doc11.

124. Bard J.D., TeKippe E.M.E. Diagnosis of Bloodstream Infections in Children//J Clin Microbiol. J Clin Microbiol, 2016. Vol. 54, N 6. P. 1418 - 1424.

125. Petty L.A. et al. Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome?//Pediatr Blood Cancer. Pediatr Blood Cancer, 2016. Vol. 63, N 7. P. 1244 - 1249.

126. Scheler M. et al. Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland//Infection. Springer Science and Business Media Deutschland GmbH, 2020. Vol. 48, N 4. P. 607 - 618.

127. Cattaneo C. et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria//Annals of Hematology, 2018 Vol. 97, p. 1717 - 1726.

128. Jaiswal S.R. et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study//Mediterr J Hematol Infect Dis. Catholic University in Rome, 2018. Vol. 10, N 1. P. 2018025.

129. Girmenia C. et al. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey//Clin Infect Dis. Clin Infect Dis, 2017. Vol. 65, N 11. P. 1884 - 1896.

130. Tang Girdwood S. et al - lactam precision dosing in critically ill children: current state and knowledge gaps//Front Pharmacol 2022; 13: 1044683.

131. Morrissey C., Gilroy N., Macesic N., Walker P., Nanda-Rajah M. et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J, 2014; 44: 1298 - 1314.

132. Groll AH, Werner C, Tebbe J, Solopova G, Becker K et al. Pulmonale Infectionen in der p diatrischen H matologie und Oncologie. Monatsschr Kinderheilkd, 2011; 159: 233 - 241.

133. Ruhnke M and Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol, 2016; 7(6): 345 - 359.

134. Tissot F., Agrawai S., Pagano L., Petrikkos G., Groll A.H. et al. ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Liekemia and Hematopoietic Stem Cell Transplant Patients. Hematologica, 2017; 102: 433 - 444.

135. Heussel C., Kauczor H., Heussel G., Fischer B., Begrich M. et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol, 1999; 17: 796 - 805.

136. Новичкова Г.А., Горонкова О.В., Балашов Д.Н., Байдильдина Д.Д., Жарикова Л.И. и др. Диагностика, клиника и лечение инвазивного аспергиллеза у детей с приобретенной апластической анемией: анализ 20 собственных случаев. Гематология и трансфузиология, январь 2005.

137. Soudani N. et al Prevalence and characteristics of acute respiratory virus infections in pediatric cancer patients//J Med Virol 2019; 91(7): 1191 - 1201.

138. Солопова Г.Г., Цыганова Е.В., Кондрашова А.В., Гордеева Г.Н., Розанцева Е.В., Бегунова С.В., Воронин К.А., Копосова А.О., Новичкова Г.А. "Особенности течения новой коронавирусной инфекции COVID-19 у детей с онкологическими, онкогематологическими и тяжелыми иммунологическими заболеваниями. Опыт НМИЦ ДГОИ им. Дмитрия Рогачева". Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021 т. 20 N 4: 89 - 99.

139. Righini-Grunder F et al/ Frequency of oral mucositis and local virus reactivation in herpes simplex virus seropositive children with myelosupressive therapy// Klin Padiatr. 2015; 227(6 - 7): 335-8.

140. Hermann B. et al. Influenza virus infection in patients with malignancies - characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Dieseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO)//European Journal of Clinical Microbiology & Infectious Diseases. Springer, 2017. Vol. 36, N 3. P. 565.

141. Spruit J L, Knight T, Sweeney C, Salimnia H, Sava an S. Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations Pediatr Hematol Oncol. 2020 Apr; 37(3): 211 - 222. doi: 10.1080/08880018.2019.1711473.

142. Tai E, Richardson LC, Townsend J, Howard E, Mcdonald LC Clostridium difficile infection among children with cancer Pediatr Infect Dis J. 2011 Jul; 30(7): 610-2.

143. Castagnola E. Et al/ Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receveiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality//Antibiotics 2021; 10(3): 266.

144. Maertens J.A. et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay//Clin Infect Dis. Clin Infect Dis, 2007. Vol. 44, N 10. P. 1329 - 1336.

145. Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L. Galactomannan, - D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016 Nov 15; 63(10): 1340 - 1348. doi: 10.1093/cid/ciw592.

146. Warris A, Lehrnbecher T Progress in the Diagnosis of Invasive Fungal Disease in Children Curr Fungal Infect Rep. 2017; 11(2): 35 - 44. doi: 10.1007/s12281-017-0274-9.

147. Gupta A, Capoor MR, Shende T, Sharma B, Mohindra R, Suri JC, Gupta DK. Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies. J Lab Physicians. 2017 Oct-Dec; 9(4): 234 - 238. doi: 10.4103/JLP.JLP_127_16.

148. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010; 14(6): R222. doi: 10.1186/cc9365.

149. Fisher BT et al Multicenter prospective study of biomarkers for diagnosis of invasive candidiasis in children and adolescents.//Clin Infect Dis 2022; 75(2): 248 - 259.

150. Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024 Feb 9: S1473-3099(23) 00731-4. doi: 10.1016/S1473-3099(23) 00731-4.

151. Freifeld A.G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america//Clin Infect Dis. Clin Infect Dis, 2011. Vol. 52, N 4.

152. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017 Jun 20; 35(18): 2082 - 2094. doi: 10.1200/JCO.2016.71.7017.

153. Lehrnbecher T. et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update//J Clin Oncol. J Clin Oncol, 2023. Vol. 41, N 9. P. 1774 - 1785.

154. Lehrnbecher T. et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation//Lancet Oncol. Lancet Oncol, 2021. Vol. 22, N 6. P. e270-e280.

155. Morales Castro D. et al. Pharmacokinetic Alterations Associated with Critical Illness//Clin Pharmacokinet. Adis, 2023. Vol. 62, N 2. P. 209 - 220.

156. Groll AH et al Fourth European conference on infections in luekaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic hematopoietic stem-cell transplantation.//Lancet.Oncol. 2014; 15: 327 - 340.

157. Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021 Jun; 22(6): e254 - e269. doi: 10.1016/S1470 - 2045(20) 30723-3.

158. Солопова Г.Г., Масчан А.А., Новичкова Г.Г. "Рекомендации 2020 года по диагностике и терапии инвазивного аспергиллеза у детей с онкогематологическими заболеваниями". Вопросы гематологии/онкологии и иммунопатологии. 2020 т. 19 N 1, стр. 158 - 166.

159. Soler-Palacin P. et al Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective trile. J Antimicrob Chemother 2012; 67(3): 700 - 706.

160. Papachristou S. et al Invasive aspergillosis in pediatric leukemia patients: prevention and treatment.//J Fungi 2019; 5(1): 14.

161. De Pauw B., Walsh T.J., Donnelly J.P., Stevens E.E., Edwards J.E. et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008; 46(12): 1813 - 1821.

162. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis, 2016; 63(4): e1 - e60.

163. Hsu AJ. Et al Challenges in the treatment of invasive aspergillosis in immunocompromised children.//Antimicrob Agents Chemother 2022; 66(7): e02156-21.

164. Cornely O., Rikan-Akdagli S., Dannaoui E., Groll A., Lagrou, K. et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect, 2014; 20 (Suppl. 3): 5 - 26.

165. Солопова Г.Г, Рачков В.Е., Ускова Н.Г., Оганесян Р.С., Коновалов Д.М. и Новичкова Г.А. Мукормикоз гастроинтестинальной локализации у пациента с острым миелобластным лейкозом. Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2014; 13(4): 69 - 74.

166. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. 2009. 448 p.

167. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients//Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, N 5. P. 903 - 913.

168. Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Vol. 2013. P. 638 - 644.

169. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

170. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88-94.

171. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia//Haematologica. 2013. Vol. 98, N 12. P. 1826 - 1835.

172. NCCN Clinical Practice Guidelines in Oncology () Prevention and Treatment of Cancer-Related InfectionsVersion 3. 2024 - September 23, 2024.

173. Strahlendorf C, Pole JD, Barber R, et al. Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study. Br J Cancer. 2018; 118: 744 - 749.

174. et al. Practical aspects of the use of intrathecal chemotherapy Aspectos de la utilizaci n de quimioterapia intratecal//Farm Hosp. 2017. Vol. 41, N 1. P. 105 - 129.

175. Байдильдина Д.Д. Острый промиелоцитарный лейкоз и его рецидивы у детей: терапия и значение молекулярно-генетического мониторинга: диссертация... кандидата медицинских наук: 14.01.08//https://new-disser.ru/_avtoreferats/01004666030.pdf.

176. Montesinos P., Diaz-Mediavilla J., Deben G., et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009; 94(9): 1242 - 1249.

177. Breccia M., Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol. 2003; 120(2): 266 - 270.

178. Hong-Hu Zhu Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocyticleukaemia: a non-inferiority, randomised phase 3 trial. The Lancet Oncology, 2018, Vol 19: 871 - 879.

179. Musa Yilmaz, Hagop Kantarjian1and, Farhad Ravand Acute promyelocytic leukemia current treatment algorithms. Blood Cancer Journal (2021) 11: 123.

180. [Alexandra Ghiaur et al. Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy. Cancers 2024, 16, 1160.

181. Mohamed Badawi Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Blood (2020) 136 (Supplement 1): 11 - 12.

182. Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented? Leukemia Research 94 (2020) 106356.

183. . et al. Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients. Leukemia & Lymphoma 2019, Dec; 60(12): 3028 - 3035.

184. Sandherr M. et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Annals of Oncology 2006, 17: 1051 - 1059.

185. Gill H. et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv. 2021 Jul 27; 5(14): 2829 - 2838.

186. Диагностика и лечение острого миелоидного лейкоза у детей/И.И. Калинина, А.А. Масчан, Ю.В. Ольшанская [и др.]; Организация-разработчик: ФГБУ НМИЦ Детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Министерства здравоохранения Российской Федерации. - Москва: Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Д. Рогачева, 2021. - 104 с. - ISBN 978-5-6047047-2-1. - EDN QTNIHQ.

187. Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients//J. Antimicrobal Chemother. 2016. Vol. 71, N 9. P. 2397-2404.

188. Pagano L., Stamouli M. et al. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry//Br J Haematol. 2015 Aug; 170(3): 434-9.

189. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients//Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, N 5. P. 903 - 913.

190. Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Vol. 2013. P. 638 - 644.

191. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.

192. Nicolas C Nicolaides; Aikaterini N Pavlaki; Maria Alexandra; George P Chrousos. Glucocorticoid Therapy and Adrenal Suppression. In the NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Last update October, 2018.

193. Selected schedules in the therapy of childhood cancers, 1st edition/G. Henze, H. Weinberger; Baxter oncology Gmbh - Berlin, 2012. - 125 p. - ISBN 976-3-927105-97-3.